Figure 5
Figure 5. IL-7 adjuvant treatment does not increase Melan-A–specific memory CD8+ T-cell responses on peptide immunization. Mice immunized with adjuvant/Melan-A26-35 were either treated with rIL-7 () or left untreated (−) during the effector phase of the immune response (days 5-13). (A) Kinetics of Melan-A–specific CD8+ T-cell responses. The number of Tet+CD8+ T cells per milliliter of blood is shown. (B) In a separate experiment, mice were treated as in panel A. All mice received BrdU in the drinking water (days 5-13). Graphs represent the kinetics of BrdU incorporation in Tet+ (left panel) and in Tet− (right panel) CD8+ T cells. The number of BrdU+ cells per milliliter of blood at the indicated time points is shown. Error bars represent SD (n = 5). The gray box in panel A indicates the IL-7 treatment period; and in panel B, the IL-7 and BrdU treatment period. *P < .05.

IL-7 adjuvant treatment does not increase Melan-A–specific memory CD8+ T-cell responses on peptide immunization. Mice immunized with adjuvant/Melan-A26-35 were either treated with rIL-7 () or left untreated (−) during the effector phase of the immune response (days 5-13). (A) Kinetics of Melan-A–specific CD8+ T-cell responses. The number of Tet+CD8+ T cells per milliliter of blood is shown. (B) In a separate experiment, mice were treated as in panel A. All mice received BrdU in the drinking water (days 5-13). Graphs represent the kinetics of BrdU incorporation in Tet+ (left panel) and in Tet (right panel) CD8+ T cells. The number of BrdU+ cells per milliliter of blood at the indicated time points is shown. Error bars represent SD (n = 5). The gray box in panel A indicates the IL-7 treatment period; and in panel B, the IL-7 and BrdU treatment period. *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal